anti-gal abundant human natural antibody multiple pathogeneses clinical benefits summary anti-gal abundant natural antibody humans constituting num immunoglobulins anti-gal naturally produced apes world monkeys ligand anti-gal carbohydrate antigen called gal epitope structure gal num gal num glcnac-r gal epitope present major carbohydrate antigen non-primate mammals prosimians world monkeys anti-gal contributes immunological pathogeneses anti-gal ige produced individuals allergies meat therapeutic monoclonal antibody cetuximab presenting gal epitopes aberrant expression gal epitope antigens mimicking humans result autoimmune processes graves disease gal epitopes produced trypanosoma cruzi interact anti-gal induce autoimmune inflammatory reactions chagas disease anti-gal igm igg mediate rejection xenografts expressing gal epitopes abundance anti-gal exploited clinical increases immunogenicity microbial vaccines e g influenza vaccine presenting gal epitopes targeting effective uptake antigen-presenting cells tumour lesions converted vaccines autologous tumour-associated antigens intra-tumoral injection gal glycolipids insert tumour cell membranes anti-gal binding gal epitopes tumour cells targets uptake antigen-presenting cells accelerated wound healing achieved application gal nanoparticles bind anti-gal activate complement recruit activate macrophages induce tissue regeneration therapy significance regeneration internally injured tissues ischaemic myocardium injured nerves 
